Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2006 2
2007 4
2008 1
2009 3
2011 4
2012 2
2013 5
2014 2
2015 1
2016 3
2018 4
2019 4
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. Among authors: alvarez secord a. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Walker JL, et al. Among authors: alvarez secord a. J Clin Oncol. 2019 Jun 1;37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19. J Clin Oncol. 2019. PMID: 31002578 Free PMC article. Clinical Trial.
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Richardson DL, et al. Among authors: alvarez secord a. JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218. JAMA Oncol. 2018. PMID: 29242937 Free PMC article. Clinical Trial.
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. Oza AM, et al. Among authors: alvarez secord a. Clin Cancer Res. 2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. Clin Cancer Res. 2020. PMID: 31831561 Free PMC article.
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Gaillard SL, et al. Among authors: alvarez secord a. Gynecol Oncol. 2019 Jul;154(1):199-206. doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13. Gynecol Oncol. 2019. PMID: 30987772
Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?
DiSilvestro P, Alvarez Secord A. DiSilvestro P, et al. Among authors: alvarez secord a. Cancer Treat Rev. 2018 Sep;69:53-65. doi: 10.1016/j.ctrv.2018.06.001. Epub 2018 Jun 5. Cancer Treat Rev. 2018. PMID: 29908480 Free article. Review.
Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
Foote J, Lopez-Acevedo M, Samsa G, Lee PS, Kamal AH, Alvarez Secord A, Havrilesky LJ. Foote J, et al. Among authors: alvarez secord a. Int J Gynecol Cancer. 2018 Feb;28(2):302-307. doi: 10.1097/IGC.0000000000001182. Int J Gynecol Cancer. 2018. PMID: 29360690
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF. Matei D, et al. Among authors: alvarez secord a. Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2. Clin Cancer Res. 2018. PMID: 29500276 Free PMC article. Clinical Trial.
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Barnett JC, Alvarez Secord A, Cohn DE, Leath CA 3rd, Myers ER, Havrilesky LJ. Barnett JC, et al. Among authors: alvarez secord a. Cancer. 2013 Oct 15;119(20):3653-61. doi: 10.1002/cncr.28283. Epub 2013 Aug 6. Cancer. 2013. PMID: 23921967 Free article.
Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ, Alvarez Secord A, Ehrisman JA, Berchuck A, Valea FA, Lee PS, Gaillard SL, Samsa GP, Cella D, Weinfurt KP, Abernethy AP, Reed SD. Havrilesky LJ, et al. Among authors: alvarez secord a. Cancer. 2014 Dec 1;120(23):3651-9. doi: 10.1002/cncr.28940. Epub 2014 Aug 4. Cancer. 2014. PMID: 25091693 Free PMC article.
42 results
Jump to page
Feedback